This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||
|
I am rapidly expanding and improving this article. Please do not delete it. (this comment is from 2011)
Not sure that the following statement is correct. I will look for support on this statement. -- Akrasia25 ( talk) 10:59, 31 March 2019 (UTC)
The list of designated orphan drugs includes such blockbuster drugs as Abilify, Provigil, Vioxx, Botox, and Cialis [1]
NOT an orphan drug.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC) It was approved by the FDA for schizophrenia on November 15, 2002 and the European Medicines Agency on 4 June 2004; for acute manic and mixed episodes associated with bipolar disorder on October 1, 2004; as an adjunct for major depressive disorder on November 20, 2007;[69] and to treat irritability in children with autism on 20 November 2009.[70] Likewise it was approved for use as a treatment for schizophrenia by the TGA of Australia in May 2003.[28]
Was an orphan drug but the reference is not that good. This one would be better.
I will add it.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
It was re-approved as an orphan drug but for a different and smaller indication. I think that it is a little misleading to say that this is a blockbuster BECAUSE it was an orphan drug. Certainly unlikely to be a blockbuster now given its troubles. This is acutally a good part of the law
In November 2017, Massachusetts-based Tremeau Pharmaceuticals announced its plan to return rofecoxib (TRM-201) to market as a treatment for hemophilic arthropathy (HA). Tremeau announced that the FDA had granted an orphan designation for TRM-201 (rofecoxib) for the treatment of HA, and that they had received FDA feedback on their development plan.[7] HA is a degenerative joint disease caused by recurrent intra-articular bleeding.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
Same as Vioxx above. The specific orphan indication came after its popularity and companies get market protection for these indications.
Based on data from thousands of patients collected by 240 investigators, Allergan received FDA approval in 1989 to market Oculinum for clinical use in the United States to treat adult strabismus and blepharospasm, using the trademark Botox.[52] This was under the 1983 US Orphan Drug Act.[53]-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
No. Always developed for ED and ED already had existing medications available so never would have been eligible for orphan status.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
References
{{
cite journal}}
: CS1 maint: unflagged free DOI (
link)
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||
|
I am rapidly expanding and improving this article. Please do not delete it. (this comment is from 2011)
Not sure that the following statement is correct. I will look for support on this statement. -- Akrasia25 ( talk) 10:59, 31 March 2019 (UTC)
The list of designated orphan drugs includes such blockbuster drugs as Abilify, Provigil, Vioxx, Botox, and Cialis [1]
NOT an orphan drug.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC) It was approved by the FDA for schizophrenia on November 15, 2002 and the European Medicines Agency on 4 June 2004; for acute manic and mixed episodes associated with bipolar disorder on October 1, 2004; as an adjunct for major depressive disorder on November 20, 2007;[69] and to treat irritability in children with autism on 20 November 2009.[70] Likewise it was approved for use as a treatment for schizophrenia by the TGA of Australia in May 2003.[28]
Was an orphan drug but the reference is not that good. This one would be better.
I will add it.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
It was re-approved as an orphan drug but for a different and smaller indication. I think that it is a little misleading to say that this is a blockbuster BECAUSE it was an orphan drug. Certainly unlikely to be a blockbuster now given its troubles. This is acutally a good part of the law
In November 2017, Massachusetts-based Tremeau Pharmaceuticals announced its plan to return rofecoxib (TRM-201) to market as a treatment for hemophilic arthropathy (HA). Tremeau announced that the FDA had granted an orphan designation for TRM-201 (rofecoxib) for the treatment of HA, and that they had received FDA feedback on their development plan.[7] HA is a degenerative joint disease caused by recurrent intra-articular bleeding.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
Same as Vioxx above. The specific orphan indication came after its popularity and companies get market protection for these indications.
Based on data from thousands of patients collected by 240 investigators, Allergan received FDA approval in 1989 to market Oculinum for clinical use in the United States to treat adult strabismus and blepharospasm, using the trademark Botox.[52] This was under the 1983 US Orphan Drug Act.[53]-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
No. Always developed for ED and ED already had existing medications available so never would have been eligible for orphan status.-- Akrasia25 ( talk) 11:19, 31 March 2019 (UTC)
References
{{
cite journal}}
: CS1 maint: unflagged free DOI (
link)